- Home
- VRNT vs RCUS Comparison
VRNT vs RCUS Comparison
Compare VRNT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- RCUS
- Stock Information
- Founded
- VRNT 1994
- RCUS 2015
- Country
- VRNT United States
- RCUS United States
- Employees
- VRNT N/A
- RCUS N/A
- Industry
- VRNT EDP Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- RCUS Health Care
- Exchange
- VRNT Nasdaq
- RCUS Nasdaq
- Market Cap
- VRNT 1.1B
- RCUS 906.4M
- IPO Year
- VRNT N/A
- RCUS 2018
- Fundamental
- Price
- VRNT $16.67
- RCUS $8.63
- Analyst Decision
- VRNT Buy
- RCUS Buy
- Analyst Count
- VRNT 6
- RCUS 10
- Target Price
- VRNT $30.33
- RCUS $23.75
- AVG Volume (30 Days)
- VRNT 1.4M
- RCUS 1.2M
- Earning Date
- VRNT 06-04-2025
- RCUS 08-07-2025
- Dividend Yield
- VRNT N/A
- RCUS N/A
- EPS Growth
- VRNT 79.53
- RCUS N/A
- EPS
- VRNT 0.84
- RCUS N/A
- Revenue
- VRNT $896,006,000.00
- RCUS $141,000,000.00
- Revenue This Year
- VRNT $7.65
- RCUS N/A
- Revenue Next Year
- VRNT $5.54
- RCUS $28.73
- P/E Ratio
- VRNT $19.76
- RCUS N/A
- Revenue Growth
- VRNT N/A
- RCUS N/A
- 52 Week Low
- VRNT $14.15
- RCUS $6.50
- 52 Week High
- VRNT $37.31
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- VRNT 39.96
- RCUS 44.17
- Support Level
- VRNT $16.23
- RCUS $8.75
- Resistance Level
- VRNT $19.65
- RCUS $9.35
- Average True Range (ATR)
- VRNT 0.87
- RCUS 0.62
- MACD
- VRNT -0.20
- RCUS -0.15
- Stochastic Oscillator
- VRNT 7.57
- RCUS 13.14
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.